CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 38 enrolled
Drug / intervention
Ivacaftor +1 moredrug
Likely dose
Ivacaftor 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03068312
NCT03068312Phase 3Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older and Have Either a 3849 + 10KB C→T or D1152H-CFTR Mutation

Vertex Pharmaceuticals Incorporated·interventional·Posted Mar 1, 2017·Updated Feb 26, 2020

In Brief

A Phase 3 clinical trial evaluating Ivacaftor and Placebo for Cystic Fibrosis. Completed, enrolled 38 participants across 1 site.

Detailed Summary

This study will evaluate the efficacy of ivacaftor treatment in subjects with CF 6 years of age and older who have a 3849 + 10KB C→T or D1152H CFTR mutation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesIsrael
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 1, 2017
Enrollment StartJul 18, 2017
Primary CompletionDec 18, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.3 years ago

Interventions

Ivacaftordrug

IVA 150 mg tablet.

Placebodrug

Placebo matched to IVA tablet.